Allergan to Acquire Elastagen to Access Next Generation Injectable Portfolio

  Allergan to Acquire Elastagen to Access Next Generation Injectable Portfolio   • Clinical stage tropoelastin platform with potential applications in aesthetics, scar remodeling and surgical wound repair • Introduces key ‘youth protein’ tropoelastin to Allergan’s Juvederm dermal filler portfolio • Provides infrastructure for further development and following approval to commercialize Elastagen’s products   SYDNEY…

Details

Elastagen to Feature Breakthrough Tissue Repair and Aesthetic Platform at Upcoming Dermatology Summit and Biotech Showcase Conferences in San Francisco, CA

Elastagen to Feature Breakthrough Tissue Repair and Aesthetic Platform at Upcoming Dermatology Summit and Biotech Showcase Conferences in San Francisco, CA Presentations by CEO Robert Daniels will present new data using tropoelastin for the treatment of stretch marks SYDNEY, AUSTRALIA – January 5, 2018 – Elastagen, a clinical-stage medical technology company with an advanced tissue…

Details

‘Squirtable’ elastic surgical glue seals wounds in 60 seconds

‘Squirtable’ elastic surgical glue seals wounds in 60 seconds Emergency treatments could be transformed, saving lives University of Sydney Wednesday 4 October 2017: A highly elastic and adhesive surgical glue that quickly seals wounds without the need for common staples or sutures could transform how surgeries are performed. Biomedical engineers from the University of Sydney…

Details

Elastagen receives $4m from NSW Health Medical Devices Fund 2016

Elastagen receives $4m from NSW Health Medical Devices Fund 2016   Jillian Skinner Minister for Health Tuesday 11 October 2016: $8.6 MILLION FOR INNOVATIVE MEDICAL DEVICES Four companies have been granted $8.6 million through the NSW Government’s Medical Devices Fund to bring their innovative medical technologies to market. Health Minister Jillian Skinner presented the fourth…

Details

Cell Innovation Partners, Japanese venture group, invests in Elastagen as part of a Second Close to the Series B Equity Financing.

Cell Innovation Partners, Japanese venture group, invests in Elastagen as part of a Second Close to the Series B Equity Financing. June 2016: Cell Innovation Partners Limited (hereinafter, “CIP”) has invested A$1 million in Elastagen Pty Ltd (hereinafter, “ELA”) (Headquarters: Sydney, Australia. CEO: Robert Daniels) through Cell Innovation Partners, L.P. ELA develops medical devices utilizing…

Details

Elastagen Completes A$13m Series B Equity Financing

Elastagen Completes A$13m Series B Equity Financing January 2016, Sydney: Elastagen Pty Ltd, a clinical stage medical company developing products based on a proprietary recombinant human tropoelastin platform technology, announces the closing of a A$13 million Series B financing round. The financing included new investors Korea Investment Partners (KIP), AMOREPACIFIC Ventures, and the Wellcome Trust.…

Details

New Grants to Support Research Commercialisaton

New grants to support research commercialisation   March 25: New research grants to help transform medical research ideas into commercial outcomes were announced today. Worth $15.2 million, the 26 NHMRC Development Grants support the commercial development of a range of products, processes and procedures that if successfully developed, will result in improved health care, disease prevention…

Details